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Abstract

Understanding the reaction mechanism of co-catalytic metallopeptidases provides a starting point for the design
and synthesis of new molecules that can be screened as potential pharmaceuticals. Many of the enzymes that
contain co-catalytic metallo-active sites play important roles in cellular processes such as tissue repair, protein
maturation, hormone level regulation, cell-cycle control and protein degradation. Therefore, these enzymes play
central roles in several disease states including cancer, HIV, stroke, diabetes, bacterial infections, neurological
processes, schizophrenia, seizure disorders, and amyotrophic lateral sclerosis. The mechanism of AAP, an
aminopeptidase from Aeromonas proteolytica, is one of the best-characterized examples of a metallopeptidase
containing a co-catalytic metallo-active site, although this enzyme is not a specific pharmaceutical target at this
time. As a large majority of co-catalytic metallopeptidases contain active sites that are nearly identical to the

one observed in AAP, the major steps of their catalytic mechanisms are likely to be very similar. With this in
mind, it is possible to propose a general catalytic mechanism for the hydrolysis of amino acid substrates.

Abbreviations

ADEPT, antibody-directed enzyme pro-drug therapy; ALS, amyotrophic lateral sclerosis; CPG2, carboxypeptidase
G2; CPG-II, carboxypeptidase G-II; FGCP, folylpoly-γ-glutamate carboxypeptidase; MDAP, meso-diaminopimelate;
MetAP, methionyl aminopeptidase; NAAG, N-acetyl-l-aspartyl-l-glutamate; PSMA, prostate-specific membrane
antigen

Introduction
Peptidases that contain co-catalytic metallo-active sites are key players in carcinogenesis, tissue repair,
neurological processes, protein maturation, hormone-level regulation, cell-cycle control and proteindegradation processes 1., 2., 3., 4.. The importance of understanding their mechanism of action is underscored
by their central role in several disease states including stroke, diabetes, cancer, HIV, bacterial infections and
neuropsychiatric disorders associated with the dysregulation of glutamatergic neurotransmission, such as
schizophrenia, seizure disorders and amyotrophic lateral sclerosis (ALS) 5., 6., 7.. For these reasons, several cocatalytic metallopeptidases have become the target of intense efforts in inhibitor design 1., 2., 3., 8.•, 9.•, 10..
However, a limiting factor in the design of tight-binding, highly specific inhibitors is the paucity of mechanistic
information available for this class of metallopeptidase.
This review focuses on recently reported mechanistic aspects of co-catalytic metallopeptidases 11., 12.. The
group can be sub-divided into endometallopeptidases and exometallopeptidases. No endometallopeptidase
containing a co-catalytic active site has been reported; therefore, only exometallopeptidases will be discussed
13., 14., 15.. Because two very detailed reviews on metalloaminopeptidases with co-catalytic active sites have
recently appeared 8.•, 16.••, only less-well characterized but physiologically important metallopeptidases with
co-catalytic active sites are discussed.

Aminopeptidases
Aminopeptidases catalyze the hydrolysis of N-terminal amino acid residues from proteins and polypeptide
chains. Several aminopeptidases have been shown to have co-catalytic metallo-active sites and these can be
split into two distinct groups on the basis of their active-site structures. The first group includes the leucine
aminopeptidases from the bovine lens (BlLAP), the porcine kidney, tomato and Escherichia coli (PepA) (Figure 1);
the second group contains the leucine aminopeptidases from Aeromonas (Vibrio) proteolytica (AAP) and from
Streptomyces griseus (SAP) (Figure 1) [17]. X-Pro aminopeptidase, AP-P, has also been classified as having a cocatalytic Mn(II) active site 18., 19.; however, it is structurally similar to methionyl aminopeptidases (MetAPs) and
X-Pro dipeptidases (prolidases), which have been suggested to contain co-catalytic Co(II) active sites on the basis
of X-ray crystallography data 20., 21., 22., 23.. Recently, MetAPs were reclassified as mononuclear Fe(II)dependent metallopeptidases, suggesting that AP-P and prolidase may also be mononuclear Fe(II) enzymes 24.,
25., 26.. In fact, AP-P was very recently shown to be fully active with only one divalent metal ion, indicating that
its metal-binding properties are similar to those of MetAP [27]. Detailed reviews discussing each of these
enzymes have recently appeared 8.•, 9.•, 16.••, 28., and therefore they are not discussed further.

Figure 1. Drawings of the active sites of the leucine aminopeptidases BlLAP (Protein Data Bank [PDB]: 1LAM),
AAP (PDB: 1AMP) and SAP (PDB: 1CP7) based on X-ray crystallography.

DppA

Aminopeptidases that are stereospecific for D-amino acids have been shown to play a central role in
peptidoglycan biosynthesis and, consequently, have emerged as potential pharmaceutical targets [29]. Only a
few D-aminopeptidases have been described and most of these are serine proteases 30., 31., 32., 33.; however,
there are a growing number of co-catalytic metallopeptidases that show specificity towards D-amino acids [29],
such as the D,D-carboxypeptidase from Streptomyces albus G, Dpd [34], and both VanX and VanY, which are
present in many enterococci [35]. The last two enzymes are important in the vancomycin resistance pathway
[35]. The D-aminopeptidase from Bacillus subtilis (DppA) exhibits specificity towards D-aminoacyl-βnaphthylamides but not L-aminoacyl-β-naphthylamides and is capable of hydrolyzing di- and tri-D-alanine
peptides [33]. DppA has been overexpressed in Escherichia coli and was suggested to be an octameric enzyme
with a molecular weight of 30 kDa/subunit [29]. The enzyme is active over a large pH range, with maximum
activity observed between pH 9.0 and pH 11.0 and a catalytic efficiency (kcat/Km) of 100 000 M−1 s−1 [29]. DppA is
inactivated by EDTA but can be reconstituted by the addition of two equivalents of Zn(II).
Recently, the X-ray crystal structure of DppA was determined at 2.4 Å resolution and revealed that DppA
crystallizes as a decamer (Figure 2) [36•]. The C-terminal domains are involved in electrostatic and hydrophobic
interactions between the two pentamers in the decamer, whereas the N-terminal domains are responsible for

inter-subunit contacts between the pentamers [36•]. A co-catalytic Zn(II) binding site resides in the N-terminal
domain of each monomer, which places the sites at the center of a 20Å channel that forms a 50Å cavity. Like
AAP, DppA’s active site consists of a (μ-aquo)(μ-carboxylato)dizinc(II) core and has a Zn–Zn distance of 3.1 Å
(Figure 3). The two Zn(II) ions are coordinated by Glu10, His60, Glu133 and His104, with Asp8 serving as the
bridging ligand. Surprisingly, there are no glutamic acid residues near the co-catalytic Zn(II) active site that can
function as the general acid/base during catalysis. However, His115 forms a hydrogen bond to the bridging
water molecule suggesting that, in DppA, a histadine residue takes the place of the glutamic acid residues
observed in AAP, SAP and carboxypeptidase A 8.•, 37., 38., 39.. Interestingly, ∼5% of the crystallized protein is
cleaved between His60 and Ser61 [29], but the significance of this cleavage and its effect on enzyme activity
remain unclear. The active site does not appear to sterically discriminate against large substrates as it resides in
a cleft 8.5 Å wide and 10 Å deep. The large active-site cleft, together with DppA’s preference for D-Ala-D-Ala,
suggests that DppA may be compartmentalized, thus preventing larger substrates from being degraded. This
suggestion is consistent with the fact that the highest activity is observed with (D-Ala)2 as the substrate, which is
released upon direct cross-linking of diaminopimelate residues in the peptidoglycan layer 40., 41.. Consequently,
it has been proposed that DppA may use (D-Ala)2 during periods of L-amino acid starvation.

Figure 2. Ribbon diagram of the X-ray crystal structure of DppA from Bacillus subtilis based on the coordinates
from the PDP (PDP: 1HI9). Zinc ions shown in pale blue.

Figure 3. Schematic of the native DppA active site based on the X-ray crystallographic coordinates (PDP: 1HI9).
The zinc ions are depicted as yellow spheres. His115, also shown, is not a metal ligand but forms a hydrogen
bond to the bridging water molecule and is thought to participate in the hydrolytic reaction.

Carboxypeptidases

Carboxypeptidases are exopeptidases that selectively cleave C-terminal amino acid residues from polypeptides
and proteins. The vast majority of metallocarboxypeptidases contain mononuclear Zn(II) active sites in which the
Zn(II) ion resides in a classic HEXXH motif 42., 43.. The detailed catalytic mechanism of mononuclear Zn(II)
carboxypeptidases has been determined on the basis of X-ray crystallographic, kinetic and spectroscopic studies
38., 44..

CPG2

Carboxypeptidase G2 (CPG2) from Pseudomonas sp. strain RS-16 (EC 3.4.17.11) also utilizes Zn(II) ions for
catalytic activity but requires two equivalents for full enzymatic activity [45]. CPG2 is a dimeric enzyme with a
mass of 42 kDa/subunit that catalyzes the hydrolytic cleavage of reduced and non-reduced folates to pteroates
and L-glutamate 45., 46.. The X-ray crystal structure of CPG2 has been determined at 2.5 Å resolution; each
monomer contains a co-catalytic Zn(II) site and a dimerization domain consisting of four anti-parallel β-sheets
flanked by two α-helices [46].
Examination of the co-catalytic Zn(II) active site of CPG2 reveals a striking similarity to the active sites of AAP,
SAP and DppA 36.•, 37., 39.. CPG2 contains two metal ions bound in its active site with a (μ-aquo)(μcarboxylato)dizinc(II) core and a Zn–Zn distance of 3.3 Å (Figure 4). The coordination geometry of each Zn(II) ion
is tetrahedral with Zn1 being liganded by a carboxylate oxygen of Glu176 and an imidazole nitrogen of His385.
Similarly, Zn2 is coordinated by a carboxylate oxygen of Glu200 and an imidazole nitrogen His112. Near the cocatalytic Zn(II) active site of CPG2 resides a glutamic acid residue (Glu175) that forms a hydrogen bond to the
bridging water molecule. Glu175 probably functions as a general acid/base during catalysis by assisting in the
activation of the water molecule, in a similar manner to Glu151 and Glu270 in AAP and CP-A, respectively 8.•,
38.. In contrast to AAP, CPG2 must accommodate the pteroate moiety of folic acid. Arg324 is also located near
the active site and may be involved in the enzyme–substrate interaction. Mutation of Arg324 to alanine resulted
in an enzyme with low activity towards methotrexate [46]. These data indicate that Arg324 is important in
catalysis but its exact role remains unknown.

Figure 4. Schematic of the active site of CPG2 from Pseudomonas sp. strain RS-16 based on the X-ray
crystallographic coordinates (PDB: 1CG2). The zinc ions are depicted as yellow spheres. Glu175, also shown, is
not a metal ligand but forms a hydrogen bond to the bridging water molecule and is thought to participate in
the hydrolytic reaction. Arg324 is also shown and is believed to participate in substrate recognition.
One of the potential medical uses of CPG2 involves the development of specific inhibitors for use in antibodydirected enzyme pro-drug therapy (ADEPT) [47]. In this procedure, a conjugate of the enzyme and an antibody
specific to proteins present in tumor cells is administered, followed by the administration of a pro-drug with
decreased toxicity compared with the actual drug. The pro-drug is converted to an active form of the drug by
the enzyme and, thus, its action is limited to cells with the conjugate attached to them [46]. As the mechanism
of action of CPG2 has not been determined, the spectrum of inhibitors that are used in medicine is limited.
General features that appear to be important include a free α-carboxylate moiety on the L-glutamate residue
and a benzene ring close to the carbonyl carbon of the amide bond 48., 49.. Thiolate-containing inhibitors based
on a thiocarbamate moiety attached to a benzene ring have also been reported for CPG2 but were only modestly
effective competitive inhibitors (Ki=0.30–165 μM) [48]; however, these compounds exhibit little toxicity towards
LS174T cells, potentially enabling their use as inhibitors in ADEPT.

GCP-II

Glutamate carboxypeptidase II (GCP-II; EC 3.4.17.21), sometimes referred to as N-acetylated-α-linked-acidic
dipeptidase, is a membrane-bound enzyme that cleaves glutamate from the neuropeptide N-acetyl-L-aspartyl-Lglutamate (NAAG) 50., 51.. Immunocytochemical studies show that GCP-II is primarily localized in the brain and
kidney; however, it is widely distributed and is abundant in neuropil, although absent from neuronal cytoplasm
[52]. GCP-II gene expression occurs mainly in astrocytes [53], and displays significant regional heterogeneity
[54]. Recently, it was shown that deletion of the gene encoding GCP-II in mice reveals a second enzyme activity
that hydrolyzes NAAG, which is consistent with GCP-II’s regional heterogeneity [55]. Because of GCP-II’s location
in the central and peripheral nervous system, it is believed to play a critical role in modulating the release of
glutamate 50., 56.. The role of NAAG has been extensively studied; among other functions, it serves as a
negative modulator of glutamatergic neurotransmission 57., 58., 59., 60.. There is also mounting evidence that
NAAG is involved in neuropsychiatric disorders associated with the dysregulation of glutamatergic
neurotransmission, such as schizophrenia, seizure disorders, Parkinson’s disease and ALS [5].
GCP-II is a trans-membrane enzyme whose activity is localized on the external surface of the cell, suggesting that
NAAG acts as a glutamate precursor and that the liberated glutamate probably acts directly on glutamate
receptors [61]. The molecular weight of GCP-II ranges from 94–100 kDa, depending on the source and on
whether the membrane-spanning sequence is present. Recently, the recombinant form of human GCP-II was
reported and the substrate specificity and kinetic properties of this enzyme were examined [62]. NAAG has a
very high affinity for GCP-II with Km values of 540 nM for the membrane-bound form and 140 nM for the soluble
enzyme. Monovalent anions such as Cl−, Br−, I−, NO3− and, to a lesser degree, F− are also required for full activity.
Chloride is likely to be the physiological activator because of its high concentration in the brain. Other oxoanions
such as phosphate and sulfate are competitive inhibitors of GCP-II with IC50 values of 100 μM and 1 mM,
respectively. GCP-II exhibits remarkable thermal stability in that the enzyme from rat brain retains 56% of its
activity after 15 min at 55°C. GCP-II also requires the presence of two equivalents of Zn(II) ions for full catalytic
activity 50., 62., 63.. Only one Zn(II) ion appears to be tightly bound to GCP-II while dithiothreitol inhibits the
enzyme. Apo-enzyme, obtained after incubation with EGTA, can be reconstituted with several first-row
transition metal ions but higher activity was observed with Mn(II) (71%) and Ni(II) (42%) than with Zn(II)-loaded
GCP-II.
No X-ray crystallographic data has been reported for GCP-II. However, on the basis of sequence comparisons
with CPG2, AAP and SAP, GCP-II has been classified as a co-catalytic metallopeptidase. Recently, the threedimensional structure of the GCP-II extracellular domain was modeled using a homology modeling approach

[64]. The proposed model is consistent with site-directed mutagenesis studies based on the crystallographically
characterized CPG2 and AAP enzymes [65]. Combined, these data suggest that the Zn(II) ligands in human GCP-II
are His377, Glu425, Asp453 and His553, with Asp387 functioning as the bridging ligand. Sequence alignments
with CPG2 and AAP as well as site-directed mutagenesis studies suggest that Glu424 is a catalytically important
residue and may function as the general acid/base during catalytic turnover [65]. In addition, Arg463, Lys499,
Lys500, Arg536 and Lys545 were suggested to constitute the recognition pocket for NAAG 64., 65.. By analogy to
AAP and SAP, Tyr552 may also be involved in the interaction with a phosphate group as phosphate inhibition
was perturbed in a Y552F mutant.
Recently, several potent and selective inhibitors of GCP-II have been designed, synthesized and used to
demonstrate that inhibition of GCP-II prevents neurodegeneration in animal models 57., 66., 67., 68., 69.. GCP-II
is thought to be more strongly inhibited by dipeptide analogs than tripeptide analogs on the basis of the
observation that L-Glu-L-Glu inhibits GCP-II activity 100 times more than L-Glu-L-Glu-L-Glu. The enzyme active
site also exhibits some stereospecificity — D-glu-D-glu is only a weak inhibitor of GCP-II. In general, N-acetylated
compounds are the most potent inhibitors of GCP-II, whereas amidation of the γ-carboxyl group reduces the
potency [50]. However, an N-acetyl group is not an absolute requirement for entry into the GCP-II active site, as
N-succinyl-glutamate also shows high affinity for GCP-II [70]. One of the most potent inhibitors of GCP-II is 2(phosphonomethyl)pentanedioic acid (2-PMPA), which exhibits a Ki of 0.28 nM and has shown robust
neuroprotective activity in both in vitro and in vivo models of ischemia 57., 67., 68., 69.. Interestingly, the
aspartate analog of 2-PMPA is ∼300 times less potent. In addition, 2-[[2-carboxyethyl)hydroxyphosphinoyl]
methyl]pentanedioic acid, which has a group similar to the aspartate present in NAAG, does not exhibit
increased potency [71]. Quisqualate, an amino acid derivative, is one of most potent inhibitors with an IC50 value
of 480 nM [62].

PSMA

One enzyme that is closely related to GCP-II and that possesses hydrolytic activity towards NAAG is human
prostate-specific membrane antigen (PSMA), whose cDNA shares 86% identity with rat brain GCP-II cDNA 60.,
72.. In addition, folylpoly-γ-glutamate carboxypeptidase (FGCP; EC 3.4.19.9), which is found in the pig and
human jejunum, is yet another gene product encoding an enzyme that is similar to GCP-II and PSMA and that is
91% identical to the latter [73]. FGCP’s primary function is to cleave dietary folylpoly-γ-glutamate that is further
absorbed at the jejunal brush border membrane.
PSMA is a 100 kDa transmembrane glutamate carboxypeptidase that removes terminal carboxy glutamates from
both neuronal NAAG and γ-linked folate polyglutamate [74]. PSMA, which is highly expressed in prostate cancer
and in the vasculature of most solid tumors, is probably involved in prostatic metastasis to lymph nodes. PMSA
is the target of several diagnostic and therapeutic strategies 74., 75., 76.. It has activity in both the membrane
and cytosolic fractions and, thus, the two enzymes are termed PSMA and PSMA′ (also called PSM′), respectively
76., 77.. Prostate carcinogenesis is associated with elevated levels of PSMA and PSMA′ enzyme activity; by
contrast, no such enhancement in PSMA activity is observed for the neoplastic changes in benign prostatic
hyperplasia. Thus, the PSMA activity enhancement observed in prostate cancer is not simply related to a
generalized prostatic hyperplasia but is specific to its malignancy.
Polysulfonated naphthlyurea suramin has been shown to possess significant antitumor activity in patients with
hormone-refractory metastatic prostate cancer [78]. The mechanism by which suramin exerts this effect is
unknown; however, suramin is a competitive inhibitor of PSMA, having Ki values of 15 nM and 68 nM for the
membrane-associated and soluble forms, respectively. This is one of the most potent activities yet described for
suramin and suggests that its pharmacologic and/or toxicological mechanism of action may involve PSMA
binding.

Desuccinylases
The meso-diaminopimelate (mDAP)/lysine biosynthetic pathway offers several potential anti-bacterial targets
that are yet to be explored 79., 80., 81., 82., 83., 84., 85.. One of the products of this pathway, lysine, is required
in protein synthesis and is also used in the peptidoglycan layer of Gram-positive bacterial cell walls. A second
product, the amino acid mDAP, is an essential component of the peptidoglycan layer for Gram-negative bacteria,
providing a link between polysaccharide strands. One of the enzymes in this pathway [86], the DapE-encoded Nsuccinyl-L,L-diaminopimelic acid desuccinylase (DapE; EC 3.5.1.18), catalyzes the hydrolysis of N-succinyl-L,Ldiaminopimelic acid to L,L-diaminopimelic acid and succinate [87]. It has been shown that deletion of the gene
encoding DapE is lethal to Helicobacter pylori and Mycobacterium smegmatis 88., 89.. Even in the presence of
lysine-supplemented media, H. pylori was unable to grow. Therefore, DapE proteins are essential for cell growth
and proliferation.
DapE proteins have been purified from E. coli and Haemophilus influenzae, and the genes that encode them
have been sequenced from Corynebacterium glutamicum, H. pylori and Mycobacterium tuberculosis. The DapE
proteins from E. coli and H. influenzae have been overexpressed in E. coli and purified to homogeneity 87., 90..
They are both small, dimeric enzymes (mass 42 kDa/subunit) and require two Zn(II) ions per mole of polypeptide
for full enzymatic activity. Alignment of all of the known gene sequences of DapE enzymes with CPG2 and AAP
sequences 39., 46., 87., 91., indicated that all of the amino acids that function as metal ligands are strictly
conserved. These data suggest that, like CPG2 and AAP, DapE should be assigned to the peptidase family M28
[17]. Like AAP and GCP-II, the purified DapE enzyme contains only one tightly bound Zn(II) ion and exhibits ∼80%
of its total activity [92]. Substitution of Zn(II) with Co(II) provides an enzyme that is hyperactive by a factor of ∼2
[87]. For both the Zn(II)- and Co(II)-bound enzymes, the Km and kcat values were determined over the pH range
6–9. A bell-shaped curve was observed and two pKa values were found at pH 6.5 and pH 8.3 with the pKa at pH
6.5 corresponding to a single proton-transfer step. Similar data have been reported for the active site
water/hydroxide nucleophile (pKa ∼7.0) of AAP [93]. Solvent kinetic isotope effect studies revealed an inverse
isotope effect that was explained by the attack of a Zn(II)-bound hydroxide on the amide carbonyl [87].

N-acetylornithine deacetylase
L-Glutamate can undergo spontaneous cyclization and conversion to L-proline via two consecutive
intermediates; however, acetylation prevents this cyclization reaction and initiates an eight-step biosynthetic
pathway for arginine 94., 95.. This arginine biosynthetic pathway is found in several bacteria including
Enterobacteriaceae [96], Myxococcus [97] and Vibrionaceae [98] and also in the thermophilic archaeon
Sulfelobus [99]. The enzyme that catalyzes the fifth step in this pathway is the N-acetyl-L-ornithine deacetylase,
ArgE [86]. ArgE catalyzes the conversion of N-acetylornithine to ornithine, which can then be incorporated into
the urea cycle. The ArgE from E. coli has been cloned, expressed and purified with a high yield 100., 101.. The
substrate specificity of ArgE is quite broad in that several α-N-acyl-L-amino acids can be hydrolyzed, including αN-acetylmethionine and α-N-formylmethionine. In fact, ArgE exhibits higher activity on these two substrates
than on α-N-acetyl-L-ornithine [100].
ArgE was shown to be a homodimer of mass 42 kDa/subunit and is activated by Zn(II) ions. Purified ArgE
contains only a single Zn(II) ion per monomer but the observed activity levels increase by a factor of ∼2 upon the
addition of excess Zn(II). Addition of Co(II) ions to apo-ArgE increases enzyme activity levels by a factor of ∼8
when compared with Zn(II)-loaded enzyme. In addition, ArgE shares significant sequence homology and
biochemical features with aacI-encoded pig aminoacylase I [102], CPG2 and DapE. Alignment of the ArgE gene
sequence with CPG2 and AAP indicates that all the amino acids that function as metal ligands are strictly
conserved [102]. The pH dependence of Km and kcat were determined for Co(II)-loaded ArgE over the pH range 5–
9. A bell-shaped curve was observed and two pKa values were found at pH 5.6 and pH 7.7. A large solvent kinetic
isotope effect was also reported for ArgE for Vmax (2.1) and a smaller solvent kinetic isotope effect of 1.3 was
observed for V/K. A linear proton inventory at pH 7.0 was also observed, suggesting that a single proton transfer

occurs in a partially rate-limiting step. No inhibitors have been reported for ArgE, but fluoride was shown to be
an uncompetitive inhibitor with a Ki of 3.4 mM.

Mechanistic insights and conclusions

Several metallopeptidases containing co-catalytic metallo-active sites are widely regarded as promising targets
for drug discovery, but the efficiency of this has been hampered by the lack of detailed mechanistic information
for this class of enzymes. However, one enzyme in this class, AAP, although not a specific pharmaceutical target,
is mechanistically one of the best-characterized co-catalytic metallopeptidases. As nearly all co-catalytic
metallopeptidases (except BlLAP and enzymes related to BlLAP) contain a (μ-aquo)(μ-carboxylato)dizinc(II) core
with one terminal carboxylate and one histidine residue at each metal site, the major steps of their catalytic
mechanisms are likely to be very similar. With this in mind, the proposed catalytic mechanism for the hydrolysis
of N-terminal amino acid residues by AAP can be generalized and applied to all metallopeptidases containing
similar co-catalytic metallo-active sites (Figure 5) [8•].

Figure 5. Proposed general mechanism for the hydrolysis of a peptide, catalyzed by a metallopeptidase with a
co-catalytic active site where R1, R2, R3 are substrate side chains and R is an N-terminal amine or a C-terminal
carboxylate. This mechanism is based on the proposed mechanism for the aminopeptidase from Aeromonas
proteolytica [8•].
The first step in catalysis is probably the recognition of the N- or C-terminal R-group of the incoming substrate
by either a hydrophobic or a hydrophilic pocket adjacent to the co-catalytic metallo-active site. Substrate
recognition pockets have been observed or predicted for all metallopeptidases containing similar co-catalytic
metallo-active sites. The second step is proposed to be the binding of the carbonyl oxygen atom of the incoming
substrate to Zn1, which can polarize the carbonyl group, rendering it susceptible to nucleophilic attack. The
bridging water/hydroxide, upon substrate binding, becomes terminal and is coordinated to Zn1. A terminal
water/hydroxide on Zn1 is the arrangement that is most consistent with the fact that nearly all enzymes in this
class are active (75–90%) with only one Zn(II) ion bound, which suggests that the substrate and the nucleophile
reside on the same Zn(II) ion. The breaking of the Zn2-OH(H) bond is probably assisted by N-terminal amine
binding in aminopeptidases and C-terminal carboxylate binding in carboxypeptidases to Zn2 whose role is simply
to position the substrate correctly in the active site. Next, a glutamic acid residue (or a histidine) located near
the catalytic active site assists in the deprotonation of the terminal water molecule, giving a nucleophilic

hydroxo moiety similar to that of Glu270 in carboxypeptidase A [38]. Once the metal-bound hydroxide has
formed, it can attack the activated carbonyl carbon, forming a gem-diolate intermediate that is stabilized by
coordination of both oxygen atoms to the co-catalytic Zn(II) site. The amide nitrogen must also be stabilized, via
a hydrogen bond, to make it a suitable leaving group. This hydrogen bond would also facilitate the collapse of
the transition state. The active site glutamate (histidine) probably supplies the additional proton to the
penultimate amino nitrogen, returning it to its ionized state. Finally, the co-catalytic Zn(II) site releases the
cleaved peptides and adds a water molecule that bridges the two metal ions. Thus, both metal ions are required
for full enzymatic activity in metallopeptidases containing co-catalytic metallo-active sites, but their individual
roles appear to differ markedly.
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